New combo therapy aims to shrink tumors in Tough-to-Treat colon cancer
NCT ID NCT07253896
Summary
This study is testing a new combination of drugs for people with advanced colorectal cancer that has spread and worsened after their first treatment. The goal is to see if adding an immunotherapy drug (AK104) to standard chemotherapy and targeted therapy can shrink tumors and control the cancer. The study will enroll about 40 patients to evaluate how well the combination works and how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Second Affiliated Hospital of Medical College of Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
the Second Affiliated Hospital of Medical College of Zhejiang University
RECRUITINGHangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.